Business Wire

Prosimo Announces General Availability of AWS Cloud WAN Integration

12.7.2022 20:52:00 EEST | Business Wire | Press release

Share

Prosimo, the Application Experience Infrastructure company, today announced the general availability of its integration with AWS Cloud WAN. This comes on the heels of AWS announcing today the general availability of AWS Cloud WAN. AWS Cloud WAN customers can now deploy the Prosimo platform to build an elastic and scalable Full Stack Cloud Transit for cross-region connectivity and segmentation to simplify and reduce operational burdens, deliver better experiences and lower costs.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220712005998/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

AWS Cloud WAN customers can now deploy the Prosimo platform to build an elastic and scalable Full Stack Cloud Transit for cross-region connectivity and segmentation to simplify and reduce operational burdens, deliver better experiences and lower costs. (Graphic: Business Wire)

"With these new features and functionality on the AXI Platform, Prosimo will be ideally suited to meet our goals: enable modern infrastructure capabilities using newer AWS networking constructs such as Cloud WAN, built-in observability for applications, and remove as much complexity as possible,” said Kevin Paige, CISO, Flexport

Enterprises can now simplify how they build and manage connectivity of their disparate environments across AWS regions across the globe, on-premises data centers, colocation facilities, branch offices, and their distributed user base with the combination of AWS Cloud WAN and Prosimo:

  • Achieve fine-grained elastic segmentation – The global network policy in AWS is kept coarse-grained and straightforward by design to be easy to manage and does not change that frequently. Fine-grained policy-based segmentation and security is the requirement from the application teams, in addition to the network layer segmentation. Prosimo helps to build policies at the per user and per-application level, on top of global network segments from Cloud WAN.
  • Hassle-free connectivity from AWS to any cloud – Regardless of how customers approach the core network policy, they will seek to achieve similar hassle-free connectivity to any of their DCs, other cloud providers, and edge co-locations. Prosimo helps extend the same core network policy model with segmentation to any cloud, including on-prem locations.
  • Modern cloud / NetDevOps operational model – Internal constituents such as modern cloud or NetDevOps teams will achieve a higher change frequency. With Prosimo’s APIs and Terraform modules, enterprise teams can integrate with their CI/CD flows for more agile development and deployment models while adhering to security and compliance guardrails and maintaining operational consistency.

Related Link: Sign up directly from the AWS Marketplace .

AWS Cloud WAN furthers Autonomous Multi-cloud Networking Solution

To ensure their multi-cloud environment is consistent, and easy-to-use, enterprises need to build an intelligent fabric that automatically connects applications, services, and networks across cloud infrastructures based on pre-set operations, security, and performance requirements. This requires first solving cloud connectivity issues then building an app transit layer that is autonomous and machine-driven to mitigate inherent complexity. Combining Network Transit and App Transit in a single architecture that simplifies and, most importantly, automates multi-cloud networking.

One Platform to Rule Them All

The combined network transit and app-to-app transit create a Full Stack Cloud Transit built on cloud-native constructs to take advantage of AWS’s global presence including AWS Cloud WAN. This gives enterprises a simpler connectivity model to migrate and connect their brownfield cloud deployments to deliver consistent, reliable, and secure Zero Trust-driven networks to support business-critical and latency-sensitive applications for users in any location.

“Our deepening relationship with AWS reflects the growing interest from AWS customers for simplified cloud networking solutions beyond just connectivity,” said Mani Ganesan, Head of Products, Prosimo. “AWS Cloud WAN and Prosimo offer a seamless and tightly integrated autonomous cloud networking solution as enterprises continue their enterprise cloud journeys and modernize their infrastructure.”

Resources

Connect with Prosimo

About Prosimo:

Prosimo delivers simplified multi-cloud infrastructure for distributed enterprise cloud journeys. Companies innovate faster and remain in control with the Prosimo integrated stack. This stack combines cloud networking, performance, security, observability, and cost management—all powered by data insights and machine learning models with autonomous cloud networking to reduce complexity and risk. Cloud-forward enterprises, including F100, have adopted Prosimo to successfully roll out revenue-generating applications, improve operational efficiency, and accelerate positive business outcomes. Prosimo is venture-backed by marquee investors such as General Catalyst and WRVI Capital. For more information, visit https://www.prosimo.io.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Press and Analyst Contact:
Matt Stubbs
Outside Labs for Prosimo
(801) 703-6626
press@prosimo.io

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye